parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 16621

HECTD2 in microglia, braak+0.58 (p 0.102) → +0.43 (p 0.247)receipt 16629
HECTD2 in dopamine neurons, braak+0.35 (p 0.349) → +0.37 (p 0.334)receipt 16630

receipt 16630: HECTD2 in dopamine neurons, braak

power: full sample +0.39 (p 0.111, n 18), 95% CI -0.10 to +0.72. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.38 (p 0.125, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.38 (p 0.120, n 18). could be the mix.
skeptic: leave-one-out range +0.31 to +0.60, sign flips 0; without severely affected donors +0.39 (p 0.111, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HECTD2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 16629: HECTD2 in microglia, braak

power: full sample +0.48 (p 0.044, n 18), 95% CI +0.02 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: +0.48 (p 0.044, n 18). holds up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.48 (p 0.046, n 18). not the mix.
skeptic: leave-one-out range +0.41 to +0.61, sign flips 0; without severely affected donors +0.48 (p 0.044, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HECTD2 in microglia.

case closed: nothing better to follow up.

loading the receipts